The triple agonism gives prescribers a mechanistic rationale for trying retatrutide in plateau cases, but this remains an area requiring individual clinical judgment
Therefore, therapeutic options that could work in a way other than classic antidepressants are being sought to increase the effectiveness of the treatment
It is up to each insurer and its chief medical officer to decide if these medications will be covered
In this context, the antitumor activity reported for incretin-based polyagonists should not be interpreted as evidence for GCGR agonism alone, but rather as an indication that coordinated multi-receptor targeting may induce favorable systemic metabolic remodeling (62,63)
Some providers are updating their approach from "absolutely avoid" to discussing the risks and benefits on a case-by-case basis
GLP-1 drugs seem to fight addiction by reducing the hormone dopamine in a brain system involved in reward, motivation and stress a system "that is co-opted or hijacked, if you will, by addiction," Al-Aly says
.webp)
